Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News JOHNSON & JOHNSON JNJ

Healthcare

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including... see more

Add To Watchlist

Recent & Breaking News (NYSE:JNJ)

Johnson & Johnson Announces Further Patent and Trademark Office Action Related to REMICADE®

PR Newswire April 29, 2015

India Joint Replacement Market to Grow in Double Digits Through 2020

PR Newswire April 27, 2015

Johnson & Johnson Announces Dividend Increase of 7.1%

PR Newswire April 23, 2015

Nodality Publishes Study Results Confirming the Company's Diagnostic Can Predict Induction Therapy Response in Elderly Patients with Acute Myeloid Leukemia

Business Wire April 21, 2015

Johnson & Johnson to Host Pharmaceutical Business Review

PR Newswire April 20, 2015

Johnson & Johnson Reports 2015 First-Quarter Results:

PR Newswire April 14, 2015

PlacementTracker Publishes Q1 2015 PIPE Market League Tables

GlobeNewswire April 9, 2015

Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution to Depomed, Inc.

PR Newswire April 2, 2015

Nodality Launches PathPro(TM) Chronic Lymphocytic Leukemia (CLL) Panels Based on Leading Single Cell Network Profiling (SCNPTM) Platform to Enhance Pharmaceutical R&D

Business Wire April 2, 2015

New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia

PR Newswire March 29, 2015

Johnson & Johnson to Webcast Annual Meeting of Shareholders

PR Newswire March 27, 2015

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

PR Newswire March 17, 2015

Johnson & Johnson Announces Strategic Investment Alliance to Combat Dementia Globally

PR Newswire March 17, 2015

Fitch Affirms Cardinal Health at 'BBB+' on Cordis Acquisition; Outlook Stable

Business Wire March 3, 2015

Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis

PR Newswire March 2, 2015

Johnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform Health Care Delivery and Improve the Patient Experience

PR Newswire February 26, 2015

Nodality Inc. Presents Data from Immuno-Oncology Program Applying Company's Novel Single Cell Network Profiling (SCNP) Platform

Business Wire February 25, 2015

Fitch: Boston Scientific's Settlement Reduces Liability Risk but Also Liquidity

Business Wire February 17, 2015

Johnson & Johnson Announces Patent and Trademark Office Action Related to REMICADE®

PR Newswire February 12, 2015

Dr. Paul Janssen Award for Biomedical Research Issues 2015 Call for Nominations

PR Newswire January 21, 2015